Analysis: AstraZeneca Pharma India Limited

What does AstraZeneca Pharma India Limited do?

• AstraZeneca Pharma India Limited is a science-led, patient-focused biopharmaceutical company dedicated to transforming healthcare through innovation.
• Operates in India for 45 years, focusing on oncology, biopharmaceuticals (CVRM, respiratory, immunology), and rare diseases.
• Committed to equitable access, sustainability, and partnerships to address unmet medical needs and strengthen healthcare systems.

• Oncology: Leading portfolio with Tagrisso, Imfinzi, Enhertu, and Lynparza for lung, breast, and GI cancers.
• Biopharmaceuticals: Focus on CVRM (Brilinta), respiratory (Fasenra, Breztri), and immunology therapies.
• Rare Diseases: Koselugo for pediatric neurofibromatosis and Soliris for PNH/aHUS.
• Digital Health: AI-driven diagnostics (lung cancer screening) and partnerships for early disease detection.

Growth thesis

Astrazeneca Pharma India is a science-led biopharma company focused on oncology (70% revenue share), biopharmaceuticals (CVRM/respiratory), and rare diseases. Oncology growth (49% YoY) will gradually cede to Forxiga (CKD/heart failure), Fasenra (asthma), and rare disease assets like Soliris and Koselugo. Over 3-4 years, 15+ new launches (Enhertu HER2-low, Imfinzi biliary cancer) and AI-driven diagnostics (1M+ scans) will scale revenue toward Rs. 3,000 crores. The Bangalore plant exit and asset-light model will improve margins, while rare disease revenue aims to replicate global 15% share by 2030. Key execution risks include regulatory delays for Soliris/Lokelma and over-reliance on oncology’s 33% YoY growth trajectory.

Why is AstraZeneca Pharma India Limited stock rising?

• target revenue of Rs. 3000 crores; timeline not specified
• oncology to remain core growth engine; ambition to be No. 1 oncology company in India
• 70% revenue share from oncology; plan to reduce reliance to 55-60% by accelerating CVRM and respiratory portfolios
• launch 15+ new assets/indications over next 3-4 years across oncology, biopharma, rare disease
• Enhertu, Imfinzi, Lynparza, Tagrisso, Brilinta, Fasenra to drive growth; multiple label expansions planned

Research report

companyname: ASTRAZEN ticker: ASTRAZEN sector: Not classified AstraZeneca Pharma India Limited (AZPIL) is the Indian listed subsidiary of global pharma giant AstraZeneca PLC. It markets and distributes patent-protected innovative medicines in India, focused on specialist-prescribed therapies in oncology, cardiovascular, respiratory, metabolism, and rare diseases. The company does not conduct its own drug discovery or primary manufacturing; it imports finished and semi-finished products from its...

Catalysts

regulatory approval, new product segment, market share gain, management upgrade

Growth guidance

No guidance

Management consistency

consistent